Fig. 3.

Tumor growth suppression with combination PTX/CER therapy in blend nanoparticles. Tumor volume change ((V _n − V _o)/V _o × 100%) over time a, b and final tumor weights b, d following a single-dose intravenous treatment of 20 mg/kg paclitaxel (PTX) and/or 80 mg/kg ceramide (CER) administered as free drug in a Cremophore EL®-ethanol formulation or encapsulated within polymer-blend nanoparticles (NP) in a, c SKOV3_TR ovarian adenocarcinoma and b, d MCF7_TR-breast-adenocarcinoma-bearing female nude mice. Control indicates no treatment. Asterisk indicates a significant difference (p < 0.05) between PTX + CER NP and control, PTX, PTX NP, and PTX + CER; Number sign indicates a significant difference (p < 0.05) between PTX + CER NP and control and PTX + CER. (n = 4 mice per treatment per tumor type)